- Home
- XENE
as of 01-27-2026 1:26pm EST
$42.29
+$0.08
+0.20%
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 3.2B | IPO Year: | 2014 |
| Target Price: | $54.09 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.74 - $46.60 | Next Earning Date: | 02-26-2026 |
| Revenue: | $7,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -33.61% |
AI-Powered XENE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 76.16%
76.16%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Xenon Pharmaceuticals Inc. (XENE)
MORTIMER IAN
Sell
PRESIDENT & CEO
XENE Jan 2, 2026
Avg Cost/Share
$44.67
Shares
40,000
Total Value
$1,777,092.86
Owned After
8,062
MORTIMER IAN
Sell
PRESIDENT & CEO
XENE Dec 8, 2025
Avg Cost/Share
$45.96
Shares
10,830
Total Value
$495,207.00
Owned After
8,062
MORTIMER IAN
Sell
PRESIDENT & CEO
XENE Dec 5, 2025
Avg Cost/Share
$45.03
Shares
14,375
Total Value
$647,306.25
Owned After
8,062
SEC Form 4
MORTIMER IAN
Sell
PRESIDENT & CEO
XENE Nov 28, 2025
Avg Cost/Share
$45.01
Shares
97
Total Value
$4,365.97
Owned After
8,062
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MORTIMER IAN | XENE | PRESIDENT & CEO | Jan 2, 2026 | Sell | $44.67 | 40,000 | $1,777,092.86 | 8,062 | |
| MORTIMER IAN | XENE | PRESIDENT & CEO | Dec 8, 2025 | Sell | $45.96 | 10,830 | $495,207.00 | 8,062 | |
| MORTIMER IAN | XENE | PRESIDENT & CEO | Dec 5, 2025 | Sell | $45.03 | 14,375 | $647,306.25 | 8,062 | |
| MORTIMER IAN | XENE | PRESIDENT & CEO | Nov 28, 2025 | Sell | $45.01 | 97 | $4,365.97 | 8,062 |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
Compare XENE vs Leading Stocks
See how XENE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.